Efficacy and safety comparison of Xalatamax and Xalatan at their use as open-angle glaucoma monotherapy

Objective: comparative evaluation of the hypotensive effect and tolerability of two latanoprost 0.005% preparations —Xalatamax of “Jadran” production and Xalatan of “Pfizer International” production at their use as open-angle glaucoma monotherapy. Materials and methods: in the study, 50 patients took part, divided into two groups depending on medication used. Follow-up period was 12 weeks. During this time, patients were examined monthly. IOP was measured, main ophthalmological and general indices were investigated, biomicroscopy and ophthalmoscopy were carried out. Patients’ compliance was constantly monitored, adverse events occurrence, drug instillation compliance, changes in patient’s state self-assessment were under hold. Study results: the level of generally accepted target pressure was practically preserved during the whole study term in both groups. Visual acuity, perimetric indices and eye fundus did not experience statistically significant changes. All patients showed almost equal compliance to treatment. At the start of the study, there were slightly more complaints to the quality of life in the group, that began Xalatamax treatment. Later on, there was a quality of life increase in both groups. In the Xalatamax group, this increase was most significant and constant. Conclusions: side effects by two types of latanoprost treatment did not significantly influence the patients’ quality of life and their attitude to treatment. The IOP-lowering efficacy of both medications to be compared turned out to be almost equal. When using Xalatamax, there was no statistically significant difference in the severity of side effects, general tolerability, and functional indices, in comparison with Xalatan.